Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
BAX's Cash to Debt is ranked higher than
52% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BAX: No Debt )
BAX' s 10-Year Cash to Debt Range
Min: 0.17   Max: No Debt
Current: No Debt

Interest Coverage 18.67
BAX's Interest Coverage is ranked higher than
63% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.80 vs. BAX: 18.67 )
BAX' s 10-Year Interest Coverage Range
Min: 3.8   Max: 32.02
Current: 18.67

3.8
32.02
WACC vs ROIC
7.74%
18.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.71
BAX's Operating margin (%) is ranked higher than
87% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.34 vs. BAX: 16.71 )
BAX' s 10-Year Operating margin (%) Range
Min: 9.41   Max: 22.9
Current: 16.71

9.41
22.9
Net-margin (%) 14.79
BAX's Net-margin (%) is ranked higher than
86% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. BAX: 14.79 )
BAX' s 10-Year Net-margin (%) Range
Min: 4.08   Max: 17.55
Current: 14.79

4.08
17.55
ROE (%) 35.71
BAX's ROE (%) is ranked higher than
94% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. BAX: 35.71 )
BAX' s 10-Year ROE (%) Range
Min: 11.12   Max: 59.01
Current: 35.71

11.12
59.01
ROA (%) 11.74
BAX's ROA (%) is ranked higher than
84% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. BAX: 11.74 )
BAX' s 10-Year ROA (%) Range
Min: 2.79   Max: 19.3
Current: 11.74

2.79
19.3
ROC (Joel Greenblatt) (%) 31.33
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.59 vs. BAX: 31.33 )
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 16.67   Max: 73.97
Current: 31.33

16.67
73.97
Revenue Growth (3Y)(%) 7.90
BAX's Revenue Growth (3Y)(%) is ranked higher than
82% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. BAX: 7.90 )
BAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.5   Max: 17.3
Current: 7.9

-3.5
17.3
EBITDA Growth (3Y)(%) 1.70
BAX's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. BAX: 1.70 )
BAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -12.2   Max: 33
Current: 1.7

-12.2
33
EPS Growth (3Y)(%) -2.80
BAX's EPS Growth (3Y)(%) is ranked higher than
85% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. BAX: -2.80 )
BAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.1   Max: 61.5
Current: -2.8

-17.1
61.5
» BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BAX Guru Trades in Q1 2014

Steven Cohen 256,874 sh (New)
David Dreman 2,453 sh (New)
Charles Brandes 204,560 sh (New)
Jeremy Grantham 3,521,356 sh (+20.6%)
Paul Tudor Jones 6,400 sh (+14.29%)
Scott Black 179,629 sh (+13.41%)
Bill Frels 2,342,265 sh (+8.66%)
Diamond Hill Capital 1,769,316 sh (+6.97%)
Bill Nygren 1,623,000 sh (+6.57%)
John Buckingham 100,126 sh (+1.44%)
Dodge & Cox 3,404 sh (+0.65%)
Murray Stahl 4,272 sh (unchged)
Jeff Auxier 25,981 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Rogers 61,251 sh (unchged)
Tweedy Browne 2,601,848 sh (unchged)
Chris Davis Sold Out
Mario Gabelli 225,500 sh (-1.03%)
Manning & Napier Advisors, Inc 216,402 sh (-5.27%)
Robert Olstein 68,000 sh (-11.69%)
Jim Simons 812,400 sh (-14.63%)
Ray Dalio 62,263 sh (-67%)
Signature Select Canadian Fund 103,600 sh (-75.82%)
Vanguard Health Care Fund 531,100 sh (-77.96%)
Jean-Marie Eveillard 1,100 sh (-85.53%)
John Hussman 7,450 sh (-93.07%)
» More
Q2 2014

BAX Guru Trades in Q2 2014

John Keeley 37,150 sh (New)
Jean-Marie Eveillard 1,000,696 sh (+90872.4%)
Paul Tudor Jones 15,503 sh (+142.23%)
Murray Stahl 9,722 sh (+127.57%)
Jim Simons 1,184,600 sh (+45.81%)
Mario Gabelli 243,400 sh (+7.94%)
Charles Brandes 209,907 sh (+2.61%)
John Buckingham 101,227 sh (+1.1%)
Manning & Napier Advisors, Inc 218,691 sh (+1.06%)
Bill Frels 2,342,897 sh (+0.03%)
John Rogers 61,251 sh (unchged)
Bill Nygren 1,623,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
David Dreman Sold Out
Vanguard Health Care Fund Sold Out
Tweedy Browne 2,592,155 sh (-0.37%)
Dodge & Cox 3,382 sh (-0.65%)
Jeff Auxier 25,331 sh (-2.5%)
Jeremy Grantham 3,397,750 sh (-3.51%)
Diamond Hill Capital 1,635,153 sh (-7.58%)
Robert Olstein 60,000 sh (-11.76%)
Scott Black 123,976 sh (-30.98%)
John Hussman 3,725 sh (-50%)
Ray Dalio 5,763 sh (-90.74%)
» More
Q3 2014

BAX Guru Trades in Q3 2014

David Dreman 3,397 sh (New)
Ray Dalio 18,463 sh (+220.37%)
John Keeley 40,650 sh (+9.42%)
Charles Brandes 225,023 sh (+7.2%)
John Rogers 63,051 sh (+2.94%)
Diamond Hill Capital 1,676,366 sh (+2.52%)
Manning & Napier Advisors, Inc 222,126 sh (+1.57%)
John Buckingham 101,959 sh (+0.72%)
Scott Black 124,346 sh (+0.3%)
Bill Nygren 1,623,000 sh (unchged)
John Hussman 3,725 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
Murray Stahl 9,722 sh (unchged)
Robert Olstein Sold Out
Bill Frels 2,336,628 sh (-0.27%)
Jean-Marie Eveillard 997,056 sh (-0.36%)
Jeff Auxier 25,231 sh (-0.39%)
Tweedy Browne 2,581,277 sh (-0.42%)
Jeremy Grantham 3,253,150 sh (-4.26%)
Mario Gabelli 224,940 sh (-7.58%)
Paul Tudor Jones 9,539 sh (-38.47%)
Jim Simons 649,700 sh (-45.15%)
Signature Select Canadian Fund 51,200 sh (-50.58%)
» More
Q4 2014

BAX Guru Trades in Q4 2014

Tweedy Browne Global Value 1,094,821 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Olstein 2014-09-30 Sold Out 0.59%$71.28 - $77 $ 70.31-6%0
David Dreman 2014-09-30 New Buy0.02%$71.28 - $77 $ 70.31-6%3397
Ray Dalio 2014-09-30 Add 220.37%0.01%$71.28 - $77 $ 70.31-6%18463
Scott Black 2014-06-30 Reduce -30.98%0.43%$71.98 - $75.45 $ 70.31-5%123976
Jean-Marie Eveillard 2014-06-30 Add 90872.4%0.18%$71.98 - $75.45 $ 70.31-5%1000696
Vanguard Health Care Fund 2014-06-30 Sold Out 0.11%$71.98 - $75.45 $ 70.31-5%0
John Keeley 2014-06-30 New Buy0.05%$71.98 - $75.45 $ 70.31-5%37150
Ray Dalio 2014-06-30 Reduce -90.74%0.03%$71.98 - $75.45 $ 70.31-5%5763
John Hussman 2014-06-30 Reduce -50%0.02%$71.98 - $75.45 $ 70.31-5%3725
David Dreman 2014-06-30 Sold Out 0.01%$71.98 - $75.45 $ 70.31-5%0
John Hussman 2014-03-31 Reduce -93.07%0.49%$66.49 - $72.85 $ 70.312%7450
Vanguard Health Care Fund 2014-03-31 Reduce -77.96%0.41%$66.49 - $72.85 $ 70.312%531100
Charles Brandes 2014-03-31 New Buy0.19%$66.49 - $72.85 $ 70.312%204560
Scott Black 2014-03-31 Add 13.41%0.17%$66.49 - $72.85 $ 70.312%179629
Ray Dalio 2014-03-31 Reduce -67%0.07%$66.49 - $72.85 $ 70.312%62263
David Dreman 2014-03-31 New Buy0.01%$66.49 - $72.85 $ 70.312%2453
Jean-Marie Eveillard 2014-03-31 Reduce -85.53%$66.49 - $72.85 $ 70.312%1100
Chris Davis 2014-03-31 Sold Out $66.49 - $72.85 $ 70.312%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc - Jul 25, 2014

We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Jan 15, 2014

Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market. 

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc
We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 15.40
BAX's P/E(ttm) is ranked higher than
90% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.50 vs. BAX: 15.40 )
BAX' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 57.43
Current: 15.4

12.15
57.43
Forward P/E 17.24
BAX's Forward P/E is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.15 vs. BAX: 17.24 )
N/A
PE(NRI) 18.80
BAX's PE(NRI) is ranked higher than
90% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.00 vs. BAX: 18.80 )
BAX' s 10-Year PE(NRI) Range
Min: 12.11   Max: 58.45
Current: 18.8

12.11
58.45
P/S 2.29
BAX's P/S is ranked higher than
76% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. BAX: 2.29 )
BAX' s 10-Year P/S Range
Min: 1.85   Max: 3.88
Current: 2.29

1.85
3.88
PFCF 51.70
BAX's PFCF is ranked higher than
85% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 58.63 vs. BAX: 51.70 )
BAX' s 10-Year PFCF Range
Min: 12.81   Max: 59.68
Current: 51.7

12.81
59.68
POCF 11.98
BAX's POCF is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.09 vs. BAX: 11.98 )
BAX' s 10-Year POCF Range
Min: 8.42   Max: 18.82
Current: 11.98

8.42
18.82
EV-to-EBIT 13.50
BAX's EV-to-EBIT is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.90 vs. BAX: 13.50 )
BAX' s 10-Year EV-to-EBIT Range
Min: 10   Max: 28.8
Current: 13.5

10
28.8
PEG 2.35
BAX's PEG is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. BAX: 2.35 )
BAX' s 10-Year PEG Range
Min: 0.65   Max: 409.33
Current: 2.35

0.65
409.33
Shiller P/E 18.28
BAX's Shiller P/E is ranked higher than
94% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 154.03 vs. BAX: 18.28 )
BAX' s 10-Year Shiller P/E Range
Min: 14.59   Max: 36.58
Current: 18.28

14.59
36.58
Days Inventory 130.16
BAX's Days Inventory is ranked higher than
64% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 118.39 vs. BAX: 130.16 )
BAX' s 10-Year Days Inventory Range
Min: 75   Max: 153.92
Current: 130.16

75
153.92
Days Sales Outstanding 61.44
BAX's Days Sales Outstanding is ranked higher than
76% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 68.35 vs. BAX: 61.44 )
BAX' s 10-Year Days Sales Outstanding Range
Min: 58.53   Max: 120.69
Current: 61.44

58.53
120.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.92
BAX's Dividend Yield is ranked higher than
84% of the 150 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. BAX: 2.92 )
BAX' s 10-Year Dividend Yield Range
Min: 1.13   Max: 3
Current: 2.92

1.13
3
Dividend Payout 0.60
BAX's Dividend Payout is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. BAX: 0.60 )
BAX' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1.07
Current: 0.6

0.27
1.07
Dividend growth (3y) 17.50
BAX's Dividend growth (3y) is ranked higher than
86% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.80 vs. BAX: 17.50 )
BAX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.5
Current: 17.5

0
22.5
Yield on cost (5-Year) 6.20
BAX's Yield on cost (5-Year) is ranked higher than
89% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.53 vs. BAX: 6.20 )
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 2.41   Max: 6.41
Current: 6.2

2.41
6.41
Share Buyback Rate 1.50
BAX's Share Buyback Rate is ranked higher than
93% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BAX: 1.50 )
BAX' s 10-Year Share Buyback Rate Range
Min: 7.7   Max: -10.6
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.97
BAX's Price/DCF (Projected) is ranked higher than
89% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. BAX: 1.97 )
BAX' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 3.94
Current: 1.97

1.1
3.94
Price/Median PS Value 0.92
BAX's Price/Median PS Value is ranked higher than
86% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. BAX: 0.92 )
BAX' s 10-Year Price/Median PS Value Range
Min: 0.79   Max: 1.62
Current: 0.92

0.79
1.62
Earnings Yield (Greenblatt) 7.40
BAX's Earnings Yield (Greenblatt) is ranked higher than
88% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. BAX: 7.40 )
BAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 10
Current: 7.4

3.5
10
Forward Rate of Return (Yacktman) 8.35
BAX's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. BAX: 8.35 )
BAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 25.4
Current: 8.35

0.8
25.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG » details
Traded in other countries:BAX.Switzerland, BTL.Germany, 0QK8.UK, BAX.Mexico,
Baxter International Inc is a Delaware corporation incorporated in 1931. The Company is a healthcare company engaged in the development, manufacture and sale of products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as bio surgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The BioScience segment faces competitors from pharmaceutical, biotechnology and other companies. The Medical Products segment faces competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Abbott: A Brighter Future Aug 28 2014 
Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
Why I Bought Baxter International Jun 19 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 


More From Other Websites
Company News for January 30, 2015 - Corporate Summary Jan 30 2015
Baxter International (BAX) Earnings Report: Q4 2014 Conference Call Transcript Jan 29 2015
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog Jan 29 2015
Baxter's (BAX) Q4 Earnings and Revenues Beat Estimates - Tale of the Tape Jan 29 2015
Baxter International Inc Earnings Call scheduled for 8:30 am ET today Jan 29 2015
Baxter Offers Disappointing Outlook Jan 29 2015
Baxter beats Street 4Q forecasts Jan 29 2015
Baxter beats Street 4Q forecasts Jan 29 2015
BAXTER INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 29 2015
Q4 2014 Baxter International Inc Earnings Release - Before Market Open Jan 29 2015
Baxter’s Fourth Quarter Financial Results Exceed Expectations Jan 29 2015
Baxter’s Fourth Quarter Financial Results Exceed Expectations Jan 29 2015
Up to Speed: Peltz receives ammo in fight against DuPont (Video) Jan 28 2015
Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog Jan 27 2015
Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog Jan 26 2015
CareFusion Banks on Pipeline Strength, Pricing Woes Remain - Analyst Blog Jan 26 2015
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Jan 22 2015
Baxter's (BAX) PHOXILLUM Solutions Get FDA Nod for CRRT - Analyst Blog Jan 21 2015
Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous... Jan 20 2015
Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous... Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK